| Literature DB >> 27600467 |
Ye Li1, Xiang-Hong Guan2, Rui Wang3, Bin Li4, Bo Ning5, Wei Su6, Tao Sun7, Hong-Yan Li1.
Abstract
BACKGROUND The aim of this study was to assess the preventive value of active ankle movements in the formation of lower-extremity deep venous thrombosis (DVT), attempting to develop a new method for rehabilitation nursing after orthopedic surgery. MATERIAL AND METHODS We randomly assigned 193 patients undergoing orthopedic surgery in the lower limbs into a case group (n=96) and a control group (n=97). The control group received routine nursing while the case group performed active ankle movements in addition to receiving routine nursing. Maximum venous outflow (MVO), maximum venous capacity (MVC), and blood rheology were measured and the incidence of DVT was recorded. RESULTS On the 11th and 14th days of the experiment, the case group had significantly higher MVO and MVC than the control group (all P<0.05). The whole-blood viscosity at high shear rate and the plasma viscosity were significantly lower in the case group than in the control group on the 14th day (both P<0.05). During the experiment, a significantly higher overall DVT incidence was recorded in the control group (8 with asymptomatic DVT) compared with the case group (1 with asymptomatic DVT) (P=0.034). During follow-up, the case group presented a significantly lower DVT incidence (1 with symptomatic DVT and 4 with asymptomatic DVT) than in the control group (5 with symptomatic DVT and 10 with asymptomatic DVT) (P=0.031). CONCLUSIONS Through increasing MVO and MVC and reducing blood rheology, active ankle movements may prevent the formation of lower-extremity DVT after orthopedic surgery.Entities:
Mesh:
Year: 2016 PMID: 27600467 PMCID: PMC5024560 DOI: 10.12659/msm.896911
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
The baseline characteristics of the case group and the control group.
| Case group (n=96) | Control group (n=97) | |||
|---|---|---|---|---|
| Age (years) | 53.6±5.4 | 54.3±6.4 | 0.819 | 0.414 |
| Gender(M/F) | 77/19 | 72/24 | 0.749 | 0.387 |
| Disease location | 0.263 | 0.877 | ||
| Left limb | 45 | 44 | ||
| Right limb | 34 | 37 | ||
| Both limbs | 17 | 15 | ||
| Anesthesia methods | 0.494 | 0.781 | ||
| General | 76 | 73 | ||
| Intravertebral | 19 | 21 | ||
| Other | 1 | 2 | ||
| Surgical site | 0.495 | 0.482 | ||
| Hip/thigh | 65 | 61 | ||
| Knee | 31 | 36 | ||
| Antithrombotic reagent | ||||
| Rivaroxaban | 12 | 9 | 0.516 | 0.472 |
| LMWH | 84 | 88 | ||
| Antibiotic (day) | 4.1±1.1 | 3.9±1.1 | 1.193 | 0.235 |
| Analgesic | 47 | 36 | 0.136 | 0.713 |
| Vitamin | 15 | 19 | 2.088 | 0.149 |
| Exercise off bed per day (min) | 53.3±6.9 | 54.9±6.2 | 1.591 | 0.113 |
| Time of lying in bed | 10.6±1.2 | 10.9±1.4 | 1.598 | 0.112 |
M – male; F – female; LMWH – low molecular weight heparin.
The maximum venous outflow (mmHg) of the case group and the control group during the experiment.
| Control group (n=97) | Case group (n=96) | |||
|---|---|---|---|---|
| 1st day | 11.84±2.02 | 12.18±2.13 | 1.135 | 0.258 |
| 2nd day | 12.06±2.78 | 12.24±2.27 | 1.398 | 0.164 |
| 5th day | 12.57±2.03 | 12.80±2.13 | 0.766 | 0.445 |
| 7th day | 12.78±2.17 | 13.10±2.27 | 0.998 | 0.319 |
| 9th day | 13.58±2.50 | 14.13±2.18 | 1.625 | 0.106 |
| 11th day | 14.08±2.88 | 14.90±2.20 | 2.217 | 0.028 |
| 14th day | 14.27±2.36 | 15.24±2.34 | 2.86 | 0.005 |
| F | 18.91 | 30.44 | – | – |
| <0.001 | <0.001 | – | – |
Refers to significant difference (P<0.05) between the case group and the control group.
The maximum venous capacity (mmHg) of the case group and the control group during the experiment.
| Control group (n=97) | Case group (n=96) | |||
|---|---|---|---|---|
| 1st day | 5.47±2.23 | 5.82±1.94 | 1.16 | 0.247 |
| 2nd day | 5.89±2.16 | 6.22±2.06 | 1.083 | 0.28 |
| 5th day | 6.40±1.89 | 6.73±1.87 | 1.216 | 0.226 |
| 7th day | 6.69±1.90 | 7.08±1.98 | 1.392 | 0.165 |
| 9th day | 7.91±2.31 | 8.36±1.87 | 1.484 | 0.14 |
| 11th day | 8.97±3.03 | 9.82±1.97 | 2.304 | 0.022 |
| 14th day | 10.13±2.53 | 11.19±2.20 | 3.098 | 0.002 |
| F | 52.44 | 94.32 | – | – |
| <0.001 | <0.001 | – | – |
Refers to significant difference (P<0.05) between the case group and the control group.
The hemorheological changes in the case group and the control group during the experiment.
| Control group (n=97) | Case group (n=96) | |
|---|---|---|
| Whole blood viscosity at high shear rate (mpas) | ||
| 1st day | 5.95±0.46 | 5.89±0.56 |
| 14th day | 5.84±0.34 | 5.62±0.48 |
| Whole blood viscosity at low shear rate (mpas) | ||
| 1st day | 12.34±0.69 | 12.29±0.78 |
| 14th day | 12.07±0.62 | 11.87±0.87 |
| Plasma viscosity (mpas) | ||
| 1st day | 2.05±0.19 | 2.01±0.21 |
| 14th day | 2.01±0.18 | 1.91±0.18 |
| Fibrinogen concentration (mpas) | ||
| 1st day | 2.12±0.52 | 2.15±0.67 |
| 14th day | 2.32±0.65 | 2.39±0.76 |
Refers to significant difference (P<0.05) of with-in group comparisons with the values detected on the 1st day
refers to significant difference (P<0.05) of between group comparisons with the values detected on the same day.
The incidence of DVT during the experiment.
| Patients with symptomatic DVT | Patients with asymptomatic DVT | Total number of DVT | ||
|---|---|---|---|---|
| Case group (n=96) | 0 (0.0%) | 1 (1.0%) | 1 (1.0%) | 0.034 |
| Control group (n=97) | 0 (0.0%) | 8 (8.2%) | 8 (8.2%) |
DVT – deep vein thrombosis.
The incidence of DVT during the follow-up.
| Patients with symptomatic DVT | Patients with asymptomatic DVT | Total number of DVT | ||
|---|---|---|---|---|
| Case group (n=96) | 1 (1.0%) | 4 (4.2%) | 5 (5.3%) | 0.031 |
| Control group (n=97) | 5 (5.2%) | 10 (10.3%) | 15 (15.5%) |
DVT – deep vein thrombosis.
Figure 1Observable limb swelling of patients with symptomatic DVT (A) and color Doppler ultrasonography for diagnosing symptomatic DVT (B).